The sensitivity of EGFR-TKI in EGFR-mutated cancer cells cultured with COLI was investigated when COLI activated mTOR via Akt and ERK1/2-independent pathway in NSCLC, leading to EGFR-TKI resistance. This evidence concerns the gene AKT1 and cancer.